Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Aytu Biopharma Inc. (AYTU) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 102 employees
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Total Value
$69,500.00
Total Shares
35,313
Average Trade Value
$8,687.50
Most Active Insider
Disbrow Joshua R.
Total Activity: $19,500
Largest Single Transaction
$19,500
by Disbrow Joshua R. on Feb 28, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Executive Officer
Officer
|
Feb 28, 2025 | 15,000 | $19,500 | 86,591 (+17.3%) | Purchase | |
|
Chief Financial Officer
|
Feb 5, 2025 | 105 | $0 | 16,000 (+0.7%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Dec 31, 2024 | 208 | $0 | 23,393 (+0.9%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Nov 11, 2024 | 14,000 | $10,000 | 15,895 (+88.1%) | Grant | |
| Nov 6, 2024 | 1,500 | $10,000 | 3,762 (+39.9%) | Grant | ||
| Nov 6, 2024 | 1,500 | $10,000 | 10,440 (+14.4%) | Grant | ||
| Nov 6, 2024 | 1,500 | $10,000 | 9,500 (+15.8%) | Grant | ||
| Nov 6, 2024 | 1,500 | $10,000 | 9,825 (+15.3%) | Grant |